BioXcel Therapeutics, Inc. (BTAI) News
Follow BioXcel Therapeutics, Inc. (BTAI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Dow falls over 100 points as US economy adds 162,000 jobs in August
The US economy created 162,000 jobs in August, above estimates of 56,000. Unemployment held at 4.1%, while average hourly earnings rose 0.3% month over month and 3.1% year over year.
MACRO | Sep 04, 2026, 02:07 PM UTC
L
Nasdaq to delist BioXcel Therapeutics after Chapter 11 filing
Nasdaq notified BioXcel Therapeutics that its common stock will be delisted due to its Chapter 11 filing on Aug. 27, 2026. Trading will be suspended at the open on Sept. 8, 2026, with a Form 25-NSE to follow.
EQUITY | Sep 01, 2026, 11:03 AM UTC
H
BioXcel files Chapter 11, names Teva stalking horse bidder
BioXcel Therapeutics began voluntary Chapter 11 proceedings and entered an asset sale agreement with Teva Pharmaceuticals International GmbH, with Teva set as stalking horse bidder in a court-supervised auction.
RATES | Aug 28, 2026, 03:06 PM UTC
M
Dow gains 100 points as Chicago PMI falls in August
The Chicago Business Barometer dipped to 47.1 in August from 57.6 previously, missing market estimates of 58.3.
MACRO | Aug 28, 2026, 02:09 PM UTC
M
BioXcel Therapeutics files for Chapter 11
BioXcel Therapeutics filed for Chapter 11 bankruptcy and shares are trading lower.
EQUITY | Aug 28, 2026, 12:40 PM UTC
H
BioXcel files for bankruptcy, agrees asset sale to Teva
BioXcel filed for bankruptcy and agreed to sell assets to Teva.
EQUITY | Aug 28, 2026, 10:30 AM UTC
L
Bioxcel Therapeutics deal with Teva includes $57.5M cash
Bioxcel Therapeutics said its deal with Teva includes $57.5 million cash and up to $67.5 million in development milestones.
EQUITY | Aug 28, 2026, 10:18 AM UTC
M
BioXcel Therapeutics selects Teva as stalking horse for $57.5M sale
BioXcel Therapeutics has picked Teva as the stalking horse for a $57.5M asset sale, with up to $87.5M in milestones.
EQUITY | Aug 28, 2026, 10:13 AM UTC
L
BioXcel Therapeutics signs asset sale agreement with Teva
BioXcel Therapeutics entered into an asset sale agreement with Teva Pharmaceuticals.
EQUITY | Aug 28, 2026, 10:07 AM UTC
L
BTAI enters asset sale agreement with Teva Pharmaceuticals
BioXcel Therapeutics (BTAI) has entered into an asset sale agreement with Teva Pharmaceuticals.
EQUITY | Aug 28, 2026, 10:00 AM UTC
H
BioXcel Therapeutics files Chapter 11 bankruptcy
BioXcel Therapeutics filed for Chapter 11 bankruptcy and estimated liabilities up to $500 million versus assets as low as $10 million.
EQUITY | Aug 28, 2026, 06:59 AM UTC
M
BioXcel Therapeutics files for bankruptcy in US
BioXcel Therapeutics filed for bankruptcy in the US.
EQUITY | Aug 28, 2026, 02:36 AM UTC